Intravenous iron therapy: A summary of treatment options and review of guidelines

Journal of Pharmacy Practice

Volumn 21, Issue 6, 2008, Pages 431-443

  Silverstein, Scott B ^a   Gilreath, Jeffrey A ^a   Rodgers, George M ^b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Erythropoietic stimulating agent; Ferric gluconate; Functional iron deficiency; Iron dextran; Iron sucrose

Indexed keywords

ANTINEOPLASTIC AGENT; DIPHENHYDRAMINE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; IRON; IRON DEXTRAN; METHYLPREDNISOLONE; PARACETAMOL; TRANSFERRIN;

ABDOMINAL PAIN; ANAPHYLAXIS; ANEMIA; ARTHRALGIA; CANCER PATIENT; CHRONIC KIDNEY DISEASE; DEATH; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FERRITIN BLOOD LEVEL; HUMAN; HYPOTENSION; INFECTION RISK; INJECTION SITE PAIN; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; IRON THERAPY; MALAISE; MYALGIA; NAUSEA; NONHUMAN; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; VOMITING;

EID: 57249114491     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190008318916     Document Type: Review

References (64)

1. Silverstein SB, Rodgers GM Parenteral iron therapy options. Am J Hematol. 2004 ; 76: 74-78.
2. Chertow GM, Mason PD, Vaage-Nilsen O., Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant. 2004 ; 19: 1571-1575.
3. Watson. INFeD1 (iron dextran injection USP) [package insert]. Morristown, NJ: Watson Pharma, Inc ; 2006.
4. Fishbane S., Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V., Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996 ; 28: 529-534.
5. Hamstra RD, Block MH, Schocket AL Intravenous iron dextran in clinical medicine. JAMA. 1980 ; 243: 1726-1731.
6. Fletes R., Lazarus JM, Gage J., Chertow GM Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis. 2001 ; 37: 743-749.
7. Laman CA, Silverstein SB, Rodgers GM Parenteral iron therapy: a single institution's experience over a 5-year period. J Natl Compr Canc Netw. 2005 ; 3: 791-795.
8. Eichbaum Q., Foran S., Dzik S. Is iron gluconate really safer than iron dextran ? Blood. 2003 ; 101: 3756-3757.
9. Bailie GR, Clark JA, Lane CE, Lane PL Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant. 2005 ; 20: 1443-1449.
10. Faich G., Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis. 1999 ; 33: 464-470.
11. Weiss G., Goodnough LT Anemia of chronic disease. New Engl J Med. 2005 ; 352: 1011-1023.
12. Maynor L., Brophy DF Risk of infection with intravenous iron therapy. Ann Pharmacother. 2007 ; 41: 1476-1480.
13. Pai AB, Boyd AV, McQuade CR, Harford A., Norenberg JP, Zager PG Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy. 2007 ; 27: 343-350.
14. Henry DH, Dahl NV, Auerbach M., Tchekmedyian S., Laufman LR Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007 ; 12: 231-242.
15. Reddy CM, Kathula SK, Ali SA, Bekal R., Walsh M. Safety and efficacy of total dose infusion of iron dextran in iron deficiency anaemia. Int J Clin Pract. 2007 ; 62: 413-415.
16. Auerbach M., Chaudhry M., Goldman H., Ballard H. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. J Lab Clin Med. 1998 ; 131: 257-260.
17. Pharmacists ASoHS. Iron preparations. In: McEvoy G, ed. AHFS Drug Information. Bethesda, MD: American Society of Health System Pharmacists ; 2006.
18. Venofer. Venofer1 (Iron Sucrose) Injection [package insert]. Shirley, NY: American Regent Laboratories, Inc ; 2006.
19. Chandler G., Harchowal J., Macdougall IC Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis. 2001 ; 38: 988-991.
20. Blaustein DA, Schwenk MH, Chattopadhyay J., et al. The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease. Kidney Int. 2003 ; 87: S72 - S77.
21. Watson. Ferrlecit1 (Sodium Ferric Gluconate Complex in Sucrose Injection) [package insert]. Corona, CA: Watson Pharma, Inc ; 2004.
22. Folkert VW, Michael B., Agarwal R., et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (> or =250 mg) administration. Am J Kidney Dis. 2003 ; 41: 651-657.
23. Coyne DW, Kapoian T., Suki W., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol. 2007 ; 18: 975-984.
24. Mittman N., Sreedhara R., Mushnick R., et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis. 1997 ; 30: 912-922.
25. Auerbach M., Winchester J., Wahab A., et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis. 1998 ; 31: 81-86.
26. Auerbach M., Ballard H., Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004 ; 22: 1301-1307.
27. Hedenus M., Birgegard G., Nasman P., et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007 ; 21: 627-632.
28. Henry DH The role of intravenous iron in cancer-related anemia. Oncology (Williston Park). 2006 ; 20 (8 suppl 6). 21-24.
29. Bastit L., Vandebroek A., Altintas S., et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008 ; 26: 1611-1618.
30. Pedrazzoli P., Farris A., Del Prete S., et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008 ; 26: 1619-1625.
31. Notebaert E., Chauny JM, Albert M., Fortier S., Leblanc N., Williamson DR Short-term benefits and risks of intravenous iron: a systematic review and meta-analysis. Transfusion. 2007 ; 47: 1905-1918.
32. Van Wyck DB, Roppolo M., Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005 ; 68: 2846-2856.
33. Cook JD, Finch CA Assessing iron status of a population. Am J Clin Nutr. 1979 ; 32: 2115-2119.
34. d'Onofrio G., Chirillo R., Zini G., Caenaro G., Tommasi M., Micciulli G. Simultaneous measurement of reticulocyte and red blood cell indices in healthy subjects and patients with microcytic and macrocytic anemia. Blood. 1995 ; 85: 818-823.
35. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006 ; 47 (5 suppl 3). S11 - S145.
36. Fishbane S., Galgano C., Langley RC Jr, Canfield W., Maesaka JK Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 1997 ; 52: 217-222.
37. Tessitore N., Solero GP, Lippi G., et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant. 2001 ; 16: 1416-1423.
38. Greer J. Wintrobe's Clinical Hematology. 11 th ed. New York: Lippincott Williams & Wilkins ; 2004: 961.
39. Wians FH Jr, Urban JE, Keffer JH, Kroft SH Discriminating between iron deficiency anemia and anemia of chronic disease using traditional indices of iron status vs transferrin receptor concentration. Am J Clin Pathol. 2001 ; 115: 112-118.
40. Statland BE, Winkel P., Bokelund H. Variation of serum iron concentration in young healthy men: within-day and day-to-day changes. Clin Biochem. 1976 ; 9: 26-29.
41. Werkman HP, Trijbels JM, Schretlen ED The "shortterm" iron rhythm. Clin Chim Acta: Int J Clin Chem. 1974 ; 53: 65-68.
42. Gordeuk VR, Brittenham GM, McLaren GD, Spagnuolo PJ Hyperferremia in immunosuppressed patients with acute nonlymphocytic leukemia and the risk of infection. J Lab Clin Med. 1986 ; 108: 466-472.
43. Bell H., Skinningsrud A., Raknerud N., Try K. Serum ferritin and transferrin saturation in patients with chronic alcoholic and non-alcoholic liver diseases. J Int Med. 1994 ; 236: 315-322.
44. Bainton DF, Finch CA The diagnosis of iron deficiency anemia. Am J Med. 1964 ; 37: 62-70.
45. Weiss G., Gordeuk VR Benefits and risks of iron therapy for chronic anaemias. Eur J Clin Invest. 2005 ; 35 (suppl 3). 36-45.
46. Lee DH, Jacobs DR Jr. Serum markers of stored body iron are not appropriate markers of health effects of iron: a focus on serum ferritin. Med Hypotheses. 2004 ; 62: 442-445.
47. Coyne D. Iron indices: what do they really mean ? Kidney Int. 2006 ; 101: S4 - S8.
48. Siimes MA, Addiego JE Jr, Dallman PR Ferritin in serum: diagnosis of iron deficiency and iron overload in infants and children. Blood. 1974 ; 43: 581-590.
49. Goodnough LT, Skikne B., Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood. 2000 ; 96: 823-833.
50. Lowenstein LM The mammalian reticulocyte. Int Rev Cytol. 1959 ; 8: 135-174.
51. Rodgers GM, Becker PS, Bennett CL, et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2008 ; 6: 536-564.
52. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008 ; 111: 25-41.
53. Bokemeyer C., Aapro MS, Courdi A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007 ; 43: 258-270.
54. Besarab A., Amin N., Ahsan M., et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000 ; 11: 530-538.
55. DeVita MV, Frumkin D., Mittal S., Kamran A., Fishbane S., Michelis MF Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol. 2003 ; 60: 335-340.
56. Ludwig H., Fritz E., Leitgeb C., Pecherstorfer M., Samonigg H., Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994 ; 84: 1056-1063.
57. Henry D., Abels R., Larholt K. Prediction of response to recombinant human erythropoietin (r-HuEPO/epoetinalpha) therapy in cancer patients. Blood. 1995 ; 85: 1676-1678.
58. Cazzola M., Messinger D., Battistel V., et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood. 1995 ; 86: 4446-4453.
59. Kasper C., Terhaar A., Fossa A., Welt A., Seeber S., Nowrousian MR Recombinant human erythropoietin in the treatment of cancer-related anaemia. Eur J Haematol. 1997 ; 58: 251-256.
60. Fishbane S., Shapiro W., Dutka P., Valenzuela OF, Faubert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int. 2001 ; 60: 2406-2411.
61. Kaneko Y., Miyazaki S., Hirasawa Y., Gejyo F., Suzuki M. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. Kidney Int. 2003 ; 63: 1086-1093.
62. Brugnara C., Zurakowski D., DiCanzio J., Boyd T., Platt O. Reticulocyte hemoglobin content to diagnose iron deficiency in children. JAMA. 1999 ; 281: 2225-2230.
63. Biesma DH, Van de Wiel A., Beguin Y., Kraaijenhagen RJ, Marx JJ Erythropoietic activity and iron metabolism in autologous blood donors during recombinant human erythropoietin therapy. Eur J Clin Invest. 1994 ; 24: 426-432.
64. Brugnara C., Chambers LA, Malynn E., Goldberg MA, Kruskall MS Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. Blood. 1993 ; 81: 956-964.